Leerink Swann initiated coverage on shares of Myovant Sciences (NYSE:MYOV) in a report published on Monday, The Fly reports. The firm issued an outperform rating and a $26.00 price target on the stock.
Several other research analysts have also recently commented on MYOV. Zacks Investment Research upgraded shares of Myovant Sciences from a hold rating to a buy rating and set a $8.25 price target for the company in a report on Saturday, August 10th. ValuEngine upgraded shares of Myovant Sciences from a hold rating to a buy rating in a report on Thursday, August 1st. Finally, Citigroup began coverage on shares of Myovant Sciences in a research report on Thursday, May 30th. They set a buy rating and a $25.00 price objective for the company. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. Myovant Sciences presently has an average rating of Buy and an average price target of $24.91.
NYSE MYOV opened at $7.93 on Monday. The company has a quick ratio of 3.42, a current ratio of 3.42 and a debt-to-equity ratio of 1.24. Myovant Sciences has a 52 week low of $6.60 and a 52 week high of $27.45. The stock has a market capitalization of $627.36 million, a PE ratio of -1.94 and a beta of 1.05. The firm has a 50 day moving average of $7.84 and a two-hundred day moving average of $15.01.
In other Myovant Sciences news, insider Frank Karbe purchased 8,000 shares of Myovant Sciences stock in a transaction that occurred on Tuesday, June 11th. The stock was purchased at an average price of $9.10 per share, for a total transaction of $72,800.00. Following the transaction, the insider now directly owns 8,000 shares in the company, valued at $72,800. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kathleen Sebelius purchased 5,000 shares of Myovant Sciences stock in a transaction that occurred on Wednesday, June 12th. The stock was acquired at an average price of $8.96 per share, with a total value of $44,800.00. Following the transaction, the director now owns 100 shares in the company, valued at $896. The disclosure for this purchase can be found here. Insiders have bought a total of 2,437,242 shares of company stock valued at $20,117,597 in the last 90 days. Insiders own 3.00% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC bought a new stake in Myovant Sciences in the second quarter valued at $60,000. Northern Trust Corp bought a new stake in Myovant Sciences in the second quarter valued at $105,000. OneAscent Financial Services LLC bought a new stake in Myovant Sciences in the second quarter valued at $172,000. Virtus ETF Advisers LLC bought a new stake in Myovant Sciences in the second quarter valued at $279,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Myovant Sciences in the second quarter valued at $330,000. Hedge funds and other institutional investors own 26.79% of the company’s stock.
About Myovant Sciences
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.